Covid-19

#Covid-19 #Flow Cytometry #Immunology / Virology & Vaccines

DDW App Note: The ZE5 Cell Analyzer in the fight against COVID-19

This paid-for app note by Bio-Rad appeared in DDW Volume 22, Issue 1 – Winter 2020/21. As COVID-19 has taken the world by storm, much has been learnt about the various aspects of viral infections ranging from immune surveillance to the therapeutic development of vaccines. One of the technologies that has… Read More

#Exclusive Content

#Covid-19 #Immunology / Virology & Vaccines

Moderna vaccine protective against UK and South African variants

Moderna has released results from in vitro neutralisation studies of sera from individuals vaccinated with its COVID-19 vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 vaccine produced neutralising titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax and Canadian government purchase agreement for COVID-19 vaccine

Novavax, the late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has finalised an agreement with the government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option… Read More

#Covid-19 #News #Trending News

#Cell and gene therapy #Covid-19

Akron Biotech agreement with Octapharma to produce virally inactivated human AB serum

Akron Biotechnology has signed an exclusive global agreement to manufacture virally inactivated human AB serum for the cell therapy market using Octaplas, Octapharma’s pooled, solvent-detergent treated human plasma. Akron Biotech is a manufacturer of cGMP-compliant ancillary materials for cell and gene therapy development and commercialisation. Switzerland-based Octapharma is one of… Read More

#News

#Antibodies #Covid-19 #Drug discovery

How to achieve accurate affinity profiling of a SARS-CoV-2 antibody in serum

Measuring antibody affinity under physiologically relevant conditions in complex mixtures like serum remains challenging but is critically important to furthering our understanding of the immune response and protection window in patients and vaccinated individuals. Fluidic Analytics’ application note explains why current technologies provide only an incomplete understanding of the… Read More

#Covid-19 #News

#Covid-19 #Vaccines

Vaccine innovation in the age of COVID-19 & beyond

Traditional approaches for vaccine discovery and development are being reimagined and accelerated - leveraging technologies in novel ways to streamline workflows and forging collaborations. Dr. Sanjay Garg and Dr. Anis H Khimani, discuss key learnings and best practices during COVID-19 vaccine research and how we can take these forward to… Read More

#Covid-19 #Exclusive Content #News

#Clinical trials #Covid-19 #Drug development

ICON supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial

ICON, provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public health organisations, has announced it provided clinical trial services to the Pfizer and BioNTech investigational COVID-19 vaccine programme. Pfizer and BioNTech announced positive efficacy results from a… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Swiss government authorises Moderna vaccine and secures 7.5 million doses

Swissmedic, the Swiss Agency for Therapeutic Products, has authorised the COVID-19 Moderna Vaccine in Switzerland. The authorisation is given according to the ordinary approvals procedure and is based on a rolling submission of data and the totality of scientific evidence shared by the company, including a data analysis from the… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Moderna vaccine becomes third COVID-19 to be approved by UK regulator

The COVID-19 vaccine developed by Moderna has been given regulatory approval for supply by the Medicines and Healthcare products Regulatory Agency (MHRA). This follows a thorough and rigorous assessment by the MHRA’s teams of scientists, including advice from the independent Commission on Human Medicines, which reviewed in depth all the… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Novavax seals agreement with Australia for 51 million doses of COVID-19 Vaccine

Novavax has executed an Advance Purchase Agreement with the Commonwealth of Australia for 51 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. This follows an agreement in principle that was announced in November 2020. NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

European Commission authorises Moderna COVID-19 vaccine in Europe

The European Commission has granted a conditional marketing authorisation (CMA) for Moderna’s COVID-19 vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union. The authorisation is based upon the recommendation of the European Medicines Agency (EMA) for use of the COVID-19 Vaccine Moderna… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Life sciences #Oncology #Therapies

The life sciences industry has learned a lot from COVID-19, but there’s more to be done

By Dr Steve Arlington, President, The Pistoia Alliance COVID-19 has dealt the life sciences a host of challenges, but it’s also been the catalyst for positive change. As the industry has turned its resources towards developing critical vaccines and therapies, organisations, governments, regulators, researchers and academia have come together in… Read More

#Editor's Choice #Exclusive Content #News #Opinion